Navigation Links
Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
Date:11/25/2013

BURLINGTON, Mass., Nov. 25, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in China, a combination of government restrictions on reimbursement and regional variations in formulary coverage heavily influence the use of premium-priced targeted therapies in the breast cancer drug market.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Decision Resources' new Emerging Markets Physician & Payer Forum report entitled Breast Cancer in China and South Korea: Physician and Payer Insight into Market Access Drivers also finds that, in South Korea—where drug coverage is widespread—national treatment guidelines are used by payers to inform appropriate reimbursement and are strictly monitored and enforced. South Korean payers express concerns about the future escalating cost of treatments for breast cancer, particularly the combination of premium-priced agents, despite their potential efficacy benefits.

According to interviewed payers in China, the large patient population size prevents breast cancer agents with a high price tag from achieving inclusion on the national formulary. While some regional formularies can choose to reimburse premium-priced therapies, they only cover a proportion of treatment costs, placing significant financial burden on patients.

"The barriers to market access in China and South Korea are contrasting," said Decision Resources Principal Analyst Amy Duval, M.Res. "In China, premium-priced agents are not covered on national formularies as the budgets cannot accommodate the number of patients who would be eligible for treatment. In South Korea, however, high cost agents for breast cancer have typically been admitted for reimbursement, although there is strict monitoring of how they are prescribed, and increasing cost pressures on payers mean that this monitoring is likely to become even more intense. Getting the payer value messaging right, so that the product is optimally positioned in terms of the specifics of NHI reimbursement, will be increasingly important in the future."  

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
2. NxStage Urges CMS to Fix Training Reimbursement to Provide Medicare Patients Greater Access to Life-Changing Home Hemodialysis Therapies
3. Efficacy Advantages and Long-Term Cost Savings Will Help Optimize Reimbursement in the EU5 for Type 2 Diabetes Agents
4. Pricing and Reimbursement in Russia
5. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
6. Approval for One Neuropathic Pain Indication is Sufficient to Support Physician Prescribing and Payer Reimbursement Across Multiple Neuropathic Pain Populations
7. Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market
8. NCPA Endorses Bipartisan Bill to Address Egregious Pharmacy Audit, Reimbursement Tactics in Medicare
9. Frost & Sullivan: Growing Reimbursement Challenges Force Hospitals to Reengineer Revenue Cycle Management
10. Reimbursement Cuts Will Challenge Japanese Interventional Cardiology Device Market
11. Home Hemodialysis Patients Urge Medicare to Fix HHD Training Reimbursement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology:
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):